Nasdaq apls.

Feb 21, 2023 · WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2022 financial results and business highlights. Find the latest dividend history for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.WALTHAM, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...The firm increased its portfolio allocation in APLS by 653.58% over the last quarter. VGHCX - Vanguard Health Care Fund Investor Shares holds 5,895K shares representing 5.01% ownership of the company.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved t...

Envestnet Asset Management Inc. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,305 shares of the company’s stock after acquiring an additional 561 shares during the quarter. Envestnet Asset Management […]The APLS stock price is -107.15% off its 52-week high price of $94.75 and 56.65% above the 52-week low of $19.83. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.29 million shares traded. The 3-month trading volume is 3.02 million shares. Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade informationApellis Pharmaceuticals, Inc. (APLS). NASDAQ: APLS · IEX Real-Time Price · USD.

CRESTWOOD, Ky. and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...

The crowded complement inhibitor field will be watching closely FDA’s decision, due Nov. 26, on C3 inhibitor pegcetacoplan from Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The therapy is one of six complement inhibitors in development for the indication, with the next in line, Zimura avacincaptad pegol from Iveric bio Inc. …The US FDA has extended by an undetermined period its review of an sNDA from Apellis Pharmaceuticals (NASDAQ:APLS) for Empaveli Injector (pegcetacoplan). The original action date was March 15.The crowded complement inhibitor field will be watching closely FDA’s decision, due Nov. 26, on C3 inhibitor pegcetacoplan from Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The therapy is one of six complement inhibitors in development for the indication, with the next in line, Zimura avacincaptad pegol from Iveric bio Inc. …08/15/2022. Option Execute. Direct. 12,500. $15.09. 55,407. Back to APLS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and ...Dec 1, 2023 · During the recent session, Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s traded shares were 1.43 million, with the beta value of the company hitting 0.96. At the last check today, the stock’s price was $57.36, reflecting an intraday gain of 6.48% or $3.49. The 52-week high for the APLS share is $ ...

APLS technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Apellis Pharmaceuticals, Inc. is based on the …

The latest price target for Apellis Pharmaceuticals ( NASDAQ: APLS) was reported by Goldman Sachs on Thursday, November 9, 2023. The analyst firm set a price target for 74.00 expecting APLS to ...

WALTHAM, Mass. and STOCKHOLM, Sweden, June 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced that the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy, in primary immune-complex …WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Under priority review status, the FDA has accepted Apellis Pharmaceuticals' (NASDAQ:APLS) marketing application seeking approval for pegcetacoplan for the treatment of paroxysmal nocturnal ...With a volume of 1,248,030, the price of APLS is up 1.39% at $51.0. RSI indicators hint that the underlying stock may be approaching overbought. Next earnings …Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.APLS U.S.: Nasdaq Apellis Pharmaceuticals Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 28, 2023 7:01 p.m. EST Delayed quote $ 46.50 -0.66 -1.40% After Hours Volume: 1...How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold.

The latest price target for Apellis Pharmaceuticals ( NASDAQ: APLS) was reported by Goldman Sachs on Thursday, November 9, 2023. The analyst firm set a price target for 74.00 expecting APLS to ...About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Nasdaq MarketSIte. Do Not Sell My Personal Information (CA ... Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Apellis Pharmaceuticals Inc (Symbol: APLS), where a total of 7,621 contracts have ...Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s stock price traded down 3.7% on Wednesday after an insider sold shares in the company. The stock traded as low as $47.20 and last traded at $47.55. 370,506 shares changed hands during trading, a decline of 86% from the average session volume of 2,690,365 shares. The stock […]NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...APLS NASDAQ. APLS NASDAQ. APLS NASDAQ. APLS NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 71.19 0.00 0.00%. The 16 analysts offering 1 year price forecasts for APLS have a max estimate of — and a min estimate of —. Analyst rating. Based on 17 …

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that specializes in discovering, developing, and selling therapeutic compounds that work by inhibiting ...2 Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock’s 52-week price range is $33 – $94. The share price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has plunged by a huge 60% in the past month, adding to the woes of its shareholders over the last year. Moreover, the stock has not done well, decreasing by 33.33% in the last six months.

WALTHAM Mass., and CRESTWOOD, Ky., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...Apellis Pharmaceuticals (NASDAQ: APLS) shares plunged Monday on the back of a short report from Citron Research, which said the "happy days are over" for the company. The short-selling firm said ...WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company and is a trending biotech stock to watch in the stock market as of late. This came after the company’s EMPAVELI ...14 нояб. 2023 г. ... Is Apellis Pharmaceuticals (NASDAQ:APLS) a buy? Compare the latest price, visualised quantitative ratios, annual reports, ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Find the latest Financials data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its first ...May 14, 2021 · WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S ...

Schwab U.S. Dividend Equity ETF. $74.3216 +0.7716 +1.05%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...

WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...

Apellis Pharmaceuticals (NASDAQ: APLS) shares plunged Monday on the back of a short report from Citron Research, which said the "happy days are over" for the company. The short-selling firm said ...Apellis Pharmaceuticals, Inc. Common Stock (APLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. APLS Latest Pre Market Trades About Latest Pre-Market Trades Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Nasdaq …On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023. The case is ...Apellis Pharmaceuticals (NASDAQ:APLS) raised ~$150m via its initial public offering ("IPO") back in November 2017, issuing just over 10.7m share at a price of $14 per share. The company described ...Find the latest Institutional Holdings data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com. For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter.CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...We challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...That number of contracts represents approximately 5.6 million underlying shares, working out to a sizeable 101.3% of VRT's average daily trading volume over the past month, of 5.5 million shares ...Dec 1, 2023 · During the recent session, Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s traded shares were 1.43 million, with the beta value of the company hitting 0.96. At the last check today, the stock’s price was $57.36, reflecting an intraday gain of 6.48% or $3.49. The 52-week high for the APLS share is $ ... Instagram:https://instagram. 23and me stock1 month tbillbest reits dividendsfarmfundr Nov 2, 2023 · Apellis Pharmaceuticals, Inc. APLS reported third-quarter 2023 loss of $1.17 per share, which was wider than the Zacks Consensus Estimate of a loss of 84 cents. The company had reported a loss of ... tastytrade vs interactive brokersdesktop metals stock price Apellis Pharmaceuticals, Inc.'s APLS newly marketed product, Syfovre (pegcetacoplan injection), was approved for the treatment of geographic atrophy (GA) secondary to age-related macular ... May 4, 2023 · Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ... tellurium stock APLS NASDAQ. APLS NASDAQ. APLS NASDAQ. APLS NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 71.19 0.00 0.00%. The 16 analysts offering 1 year price forecasts for APLS have a max estimate of — and a min estimate of —. Analyst rating. Based on 17 …Jul 6, 2023 · Fintel reports that on July 21, 2023, HC Wainwright & Co. maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy recommendation. Analyst Price Forecast Suggests 203.86% Upside. As ...